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Neuroendocrine carcinomas (NECs) are rare neoplasms with an increasing
incidence. Oncogenetic pathways of colorectal NEC are still poorly understood, and
no treatment standards are available for these rare tumors.
METHODS:
We analyzed retrospectively the clinical records and histology of 12 patients with
colorectal NEC. KRAS and BRAF mutations were investigated after the dissection of
exoendocrine and neuroendocrine components. ALK alterations and EML4-ALK
transcripts were detected by in-situ hybridization and determination of fusion
transcripts, respectively.
RESULTS:
At the time of diagnosis, the mean age of the patients was 60 years (40-79) and 10
patients had synchronous metastases. A transient response occurred in two patients
and one patient treated with cisplatin-etoposide or fluoropyrimidine-oxaliplatin,
respectively. Tumor progression-related death occurred in 11 of 12 patients. Ten
tumors contained an exocrine component, accounting for 5-70% of the tumor, and
the other two contained an amphicrine component. BRAF/KRAS mutations were
found in six of 10 tumors, corresponding to BRAF(V600E) (n=2) or KRAS(G12D)
(n=2), KRAS(G12V) or KRAS(G13D). DNA was obtained from both exocrine and
endocrine components in seven cases, and the BRAF/KRAS status was identical in
all cases. Split of the ALK locus was detected in a minority of tumor cells in two of
eight cases, but EML4-ALK transcripts were absent.
CONCLUSION:
The association of an exocrine component in all cases and the similar profile of
BRAF/KRAS mutations indicate that colorectal NEC may correspond to a high-grade
transformation of colorectal carcinoma. New chemotherapy regimens using
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